RU2002119589A - Virulence genes and proteins and their use - Google Patents

Virulence genes and proteins and their use

Info

Publication number
RU2002119589A
RU2002119589A RU2002119589/13A RU2002119589A RU2002119589A RU 2002119589 A RU2002119589 A RU 2002119589A RU 2002119589/13 A RU2002119589/13 A RU 2002119589/13A RU 2002119589 A RU2002119589 A RU 2002119589A RU 2002119589 A RU2002119589 A RU 2002119589A
Authority
RU
Russia
Prior art keywords
strain
peptide
peptide according
paragraphs
polynucleotide
Prior art date
Application number
RU2002119589/13A
Other languages
Russian (ru)
Other versions
RU2240327C2 (en
Inventor
Энда Элизабет КЛАРК (GB)
Энда Элизабет КЛАРК
Ликуинг ЗХОУ (GB)
Ликуинг ЗХОУ
Жаклин Элизабет ШИА (GB)
Жаклин Элизабет ШИА
Роберт Грэхэм ФЕЛДМАН (GB)
Роберт Грэхэм ФЕЛДМАН
Дэвид Вилль м ХОЛДЕН (GB)
Дэвид Вилльям ХОЛДЕН
Original Assignee
Вмакс Лимитед (Gb)
Вмакс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930469.3A external-priority patent/GB9930469D0/en
Priority claimed from GBGB9930466.9A external-priority patent/GB9930466D0/en
Priority claimed from GBGB9930462.8A external-priority patent/GB9930462D0/en
Priority claimed from GBGB9930474.3A external-priority patent/GB9930474D0/en
Priority claimed from GBGB9930472.7A external-priority patent/GB9930472D0/en
Priority claimed from GBGB9930476.8A external-priority patent/GB9930476D0/en
Priority claimed from GBGB9930463.6A external-priority patent/GB9930463D0/en
Priority claimed from GB0003726A external-priority patent/GB0003726D0/en
Priority claimed from GB0003730A external-priority patent/GB0003730D0/en
Priority claimed from GB0003728A external-priority patent/GB0003728D0/en
Priority claimed from GB0003733A external-priority patent/GB0003733D0/en
Priority claimed from GB0003731A external-priority patent/GB0003731D0/en
Priority claimed from GB0010587A external-priority patent/GB0010587D0/en
Application filed by Вмакс Лимитед (Gb), Вмакс Лимитед filed Critical Вмакс Лимитед (Gb)
Publication of RU2002119589A publication Critical patent/RU2002119589A/en
Publication of RU2240327C2 publication Critical patent/RU2240327C2/en
Application granted granted Critical

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (26)

1. Пептид, кодируемый опероном, включающим любую из нуклеотидных последовательностей, идентифицированных как SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59 и 61 S. pyogenes, или родственная молекула в грам-положительной бактерии, имеющая, по крайней мере, 40%-ное сходство или идентичность на пептидном или нуклеотидном уровне, или его функциональный фрагмент, используемые в терапевтических или диагностических целях.1. The peptide encoded by an operon comprising any of the nucleotide sequences identified as SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 , 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61 S. pyogenes, or a related molecule in a gram-positive bacterium, having at least 40 % similarity or identity at the peptide or nucleotide level, or a functional fragment thereof, used for therapeutic or diagnostic purposes. 2. Пептид по п.1, отличающийся тем, что сходство или идентичность последовательностей составляют, по крайней мере, 60%.2. The peptide according to claim 1, characterized in that the similarity or identity of the sequences is at least 60%. 3. Пептид по п.1 или 2, отличающийся тем, что сходство или идентичность последовательностей составляют, по крайней мере, 90%.3. The peptide according to claim 1 or 2, characterized in that the similarity or identity of the sequences is at least 90%. 4. Пептид по п.1, содержащий аминокислотную последовательность, идентифицированную как SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 50, 52, 54, 56, 58, 60 или 62.4. The peptide according to claim 1, containing the amino acid sequence identified as SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 50, 52, 54, 56, 58, 60, or 62. 5. Пептид по любому из пп.1-4, используемый для изготовления лекарственного средства для лечения или профилактики состояния, ассоциированного с инфекцией, вызываемой стрептококками или грам-положительными бактериями.5. The peptide according to any one of claims 1 to 4, used for the manufacture of a medicament for the treatment or prophylaxis of a condition associated with an infection caused by streptococci or gram-positive bacteria. 6. Пептид по п.5, отличающийся тем, что состоянием является пневмония.6. The peptide according to claim 5, characterized in that the condition is pneumonia. 7. Пептид по п.5 или 6, используемый в ветеринарии.7. The peptide according to claim 5 or 6, used in veterinary medicine. 8. Пептид по любому из пп.1-4, используемый в анализе-скрининге для идентификации противомикробного лекарственного средства.8. The peptide according to any one of claims 1 to 4, used in a screening assay to identify an antimicrobial drug. 9. Полинуклеотид, кодирующий пептид по любому из пп.1-4, используемый в терапевтических или диагностических целях.9. Polynucleotide encoding the peptide according to any one of claims 1 to 4, used for therapeutic or diagnostic purposes. 10. Полинуклеотид по п.9, встроенный в клетку-хозяин.10. The polynucleotide according to claim 9, embedded in the host cell. 11. Полинуклеотид по п.9, используемый для изготовления лекарственного средства для лечения или профилактики состояния, ассоциированного с инфекцией, вызываемой стрептококками или грам-положительными бактериями.11. The polynucleotide according to claim 9, used for the manufacture of a medicament for the treatment or prevention of a condition associated with an infection caused by streptococci or gram-positive bacteria. 12. Полинуклеотид по п.11, отличающийся тем, что состоянием является пневмония.12. The polynucleotide according to claim 11, characterized in that the condition is pneumonia. 13. Полинуклеотид по п.11 или 12, используемый в ветеринарии.13. The polynucleotide according to claim 11 or 12, used in veterinary medicine. 14. Полинуклеотид по п.9, используемый в анализе-скрининге для идентификации противомикробного лекарственного средства.14. The polynucleotide of claim 9, used in a screening assay for identifying an antimicrobial drug. 15. Стрептококковый штамм группы А, содержащий мутацию, которая нарушает экспрессию любой из нуклеотидных последовательностей, кодируемых пептидом по п.1.15. A streptococcal strain of group A containing a mutation that disrupts the expression of any of the nucleotide sequences encoded by the peptide according to claim 1. 16. Штамм по п.15, отличающийся тем, что мутацией является инсерционная инактивация или делеция гена.16. The strain of claim 15, wherein the mutation is insertional inactivation or deletion of the gene. 17. Штамм по п.15 или 16, используемый в терапевтических или диагностических целях.17. The strain of claim 15 or 16, used for therapeutic or diagnostic purposes. 18. Штамм по любому из пп.15-17, включающий мутацию в дополнительной нуклеотидной последовательности.18. The strain according to any one of paragraphs.15-17, comprising a mutation in an additional nucleotide sequence. 19. Штамм по любому из пп.15-18, содержащий гетерологичный антиген, терапевтический пептид или нуклеиновую кислоту.19. The strain according to any one of paragraphs.15-18, containing a heterologous antigen, therapeutic peptide or nucleic acid. 20. Штамм по любому из пп.15-19, используемый для изготовления лекарственного средства для лечения или профилактики состояния, ассоциированного с инфекцией, вызываемой стрептококками или грам-положительными бактериями.20. The strain according to any one of paragraphs.15-19, used for the manufacture of a medicinal product for the treatment or prevention of a condition associated with an infection caused by streptococci or gram-positive bacteria. 21. Штамм по п.20, отличающийся тем, что состоянием является пневмония.21. The strain according to claim 20, characterized in that the condition is pneumonia. 22. Штамм по п.20 или 21, используемый в ветеринарии.22. The strain of claim 20 or 21, used in veterinary medicine. 23. Штамм по любому из пп.15-19, используемый в анализе-скрининге для идентификации противомикробного лекарственного средства.23. The strain according to any one of paragraphs.15-19, used in the screening assay for identifying an antimicrobial drug. 24. Вакцина, включающая пептид по любому из пп.1-4 или средства для его экспрессии.24. A vaccine comprising the peptide according to any one of claims 1 to 4 or a means for its expression. 25. Вакцина, включающая штамм по любому из пп.15-19.25. A vaccine comprising a strain according to any one of paragraphs.15-19. 26. Антитело, индуцированное против пептида по любому из пп.1-4.26. The antibody induced against the peptide according to any one of claims 1 to 4.
RU2002119589/13A 1999-12-23 2000-12-22 Gene and protein of virulence and their using RU2240327C2 (en)

Applications Claiming Priority (38)

Application Number Priority Date Filing Date Title
GBGB9930466.9A GB9930466D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein,and their use
GB9930473.5 1999-12-23
GB9930462.8 1999-12-23
GB9930471.9 1999-12-23
GBGB9930476.8A GB9930476D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein,and their use
GB9930467.7 1999-12-23
GB9930469.3 1999-12-23
GB9930472.7 1999-12-23
GB9930463.6 1999-12-23
GB9930466.9 1999-12-23
GBGB9930463.6A GB9930463D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein and their use
GB9930474.3 1999-12-23
GBGB9930462.8A GB9930462D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein and their use
GBGB9930469.3A GB9930469D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein,and their use
GB9930475.0 1999-12-23
GBGB9930472.7A GB9930472D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein,and their use
GB9930476.8 1999-12-23
GBGB9930474.3A GB9930474D0 (en) 1999-12-23 1999-12-23 Virulence gene and protein, and their use
GB9930464.4 1999-12-23
GB0003726A GB0003726D0 (en) 2000-02-17 2000-02-17 Virulence gene and protein and their use
GB0003730A GB0003730D0 (en) 2000-02-17 2000-02-17 Virulence gene and protein, and their use
GH0003727.5 2000-02-17
GB0003726.7 2000-02-17
GB0003725.9 2000-02-17
GB0003732.5 2000-02-17
GB0003728A GB0003728D0 (en) 2000-02-17 2000-02-17 Virulence gene and protein, and their use
GB0003731.7 2000-02-17
GB0003730.9 2000-02-17
GB0003733.3 2000-02-17
GB0003733A GB0003733D0 (en) 2000-02-17 2000-02-17 Virulence gene and protein, and their use
GB0003736.6 2000-02-17
GB0003729.1 2000-02-17
GB0003728.3 2000-02-17
GB0003735.8 2000-02-17
GB0003731A GB0003731D0 (en) 2000-02-17 2000-02-17 Virulence gene and protein, and their use
GB0010587A GB0010587D0 (en) 2000-05-02 2000-05-02 Virulence gene and protein, and their use
GB0010587.4 2000-05-02
GB0010585.8 2000-05-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2004119947/13A Division RU2004119947A (en) 1999-12-23 2004-06-30 GENES AND PROTEINS OF VIRULENCE AND THEIR USE

Publications (2)

Publication Number Publication Date
RU2002119589A true RU2002119589A (en) 2004-02-10
RU2240327C2 RU2240327C2 (en) 2004-11-20

Family

ID=34317885

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2002119589/13A RU2240327C2 (en) 1999-12-23 2000-12-22 Gene and protein of virulence and their using
RU2004119947/13A RU2004119947A (en) 1999-12-23 2004-06-30 GENES AND PROTEINS OF VIRULENCE AND THEIR USE

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2004119947/13A RU2004119947A (en) 1999-12-23 2004-06-30 GENES AND PROTEINS OF VIRULENCE AND THEIR USE

Country Status (1)

Country Link
RU (2) RU2240327C2 (en)

Also Published As

Publication number Publication date
RU2240327C2 (en) 2004-11-20
RU2004119947A (en) 2006-01-10

Similar Documents

Publication Publication Date Title
Timoney The pathogenic equine streptococci
RU2005101623A (en) VIRULENT GENES, PROTEINS AND THEIR APPLICATION
US20050232942A1 (en) Virulence genes, proteins, and their use
RU2002132891A (en) VIRULENT GENES, PROTEINS AND THEIR APPLICATION
CN108135992A (en) Immunogenic fusion proteins
US8246964B2 (en) Antigenic protein fragments of Streptococcus pneumoniae
NZ526879A (en) Genes and proteins, and their use
Kling et al. Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus
CN107050442B (en) Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
RU2002119589A (en) Virulence genes and proteins and their use
Siu et al. Epidemiology of invasive pneumococcal infection in Taiwan: antibiotic resistance, serogroup distribution, and ribotypes analyses
RU2003107837A (en) GENES AND PROTEINS AND THEIR APPLICATIONS
RU2701733C1 (en) Live vaccine based on enterococcus faecium l3 probiotic strain for prevention of infection caused by streptococcus pneumonie
US20040073000A1 (en) Genes and proteins, and their uses
Wadhwani et al. In silico identification of novel potential vaccine candidates in Streptococcus pneumoniae
AU2001282299A1 (en) Genes and proteins, and their uses
ES2282254T3 (en) VIRULENCE GENES, PROTEINS AND ITS USE.
Oulad et al. Polymorphism of ompH gene of Pasteurella multocida serotype A strains isolated in Iran
RU2006145224A (en) GENES AND PROTEINS AND THEIR APPLICATIONS
CN115433723A (en) Recombinant protein, vaccine and medicament for preventing gram-positive pathogenic bacteria
Moloney Molecular typing of Irish Streptococcus equi ssp equi strains
RU2000114245A (en) NEISSERIA ANTIGENS
WO2002077020A2 (en) Virulence genes in h. influenzae
Shlaes et al. coccal endocarditis, S. milleri accounts for only about 5%. More
AU2007202896A1 (en) Genes and proteins, and their uses

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20091223